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Introduction
By controlling the release of antiproliferative drugs from a polymer surface, fi rst-generation drug-eluting stents (DES) reduce the risk of restenosis and the need for repeat revascularisation compared with bare-metal stents, 1-3 but at the expense of an increased risk of very late (>1 year) stent thrombosis. 4,5 Incomplete endothelialisation of the stent struts and positive vessel remodelling due to chronic infl ammation might cause this thrombosis, because the persistence of polymer material on fi rst-generation DES after completed drug release might trigger an infl ammatory response. 6, 7 Biodegradable polymer DES aim to overcome this problem by providing similar controlled drug release with subsequent degradation of the polymer. Umirolimus (commonly known as biolimus)-eluting stents were designed with a bio degradable polymer applied to the non-luminal surface of the stent. After implantation, the polymer is metab olised to water and carbon dioxide within 9 months. 8, 9 Biolimus is a highly lipophilic sirolimus analogue that inhibits proliferation of smooth muscle cells.
A biodegradable polymer biolimus-eluting stent was assessed in the Limus Eluted from A Durable versus ERodable Stent coating (LEADERS) trial 10, 11 and was reported to be non-inferior to the durable polymer sirolimus-eluting Cypher stent (Cordis, Miami Lakes, FL, USA) with respect to clinical safety and effi cacy outcomes up until 4 years' follow-up. The Intracoronary Stenting and Angiographic Results (ISAR-TEST 4) trial 12 compared a biodegradable polymer stent (with a natural resin eluting sirolimus) with the durable polymer sirolimuseluting Cypher stent and reported no signifi cant diff erences in outcomes between the stents. 12 The Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V trial aimed to further investigate the eff ects of a third-generation biodegradable biolimus-eluting stent compared with a fi rst-generation durable polymer-coated sirolimuseluting stent in a population-based setting, using registry detection of clinically driven events. 13, 14 Methods Study design and patients SORT OUT V is a randomised, multicentre, all-comer, two-arm, non-inferiority trial comparing a biolimuseluting stent with a sirolimus-eluting stent to treat coronary artery stenosis, undertaken at three hospitals across western Denmark. We used western Denmark registry data 15, 16 to compare randomised and nonrandomised patients during the study period so that we could assess how generalisable our study results would be (appendix). 17 Eligible patients were aged 18 years or older, had chronic stable coronary artery disease or acute coronary syn dromes, and at least one coronary artery lesion with more than 50% diameter stenosis needing treatment with a DES. We did not place restrictions on the number of lesions or vessels to be treated, or lesion length. Exclusion criteria were life expectancy of less than 1 year; allergy to aspirin, clopidogrel, prasugrel, sirolimus, or biolimus; participation in another randomised trial; clinical indications of an inability to tolerate dual antiplatelet treatment for 12 months; or inability to provide written informed consent.
The study complied with the Declaration of Helsinki and was approved by the Central Region Denmark ethics committee. All patients provided written informed consent for trial participation.
Randomisation
We enrolled patients and randomly allocated them to treatment groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block randomisation by centre was used to assign patients (1:1) to receive a biolimus-eluting stent (Nobori, Terumo, Tokyo, Japan) or a sirolimus-eluting stent (Cypher Select Plus, Cordis, Johnson & Johnson, Warren, NJ, USA). The allocation sequence was computer-generated by an independent organisation, and was stratifi ed by sex, presence of diabetes, and presence of ST-segment elevation myocardial infarction. Patients were assigned to treatment through an automated telephone allocation service. Although operators were not masked, all individuals analysing data were masked to treatment assignment.
Procedures
The biolimus-eluting stent was available in three diameters (2·50 mm, 3·00 mm, 3·50 mm) and fi ve lengths (8 mm, 14 mm, 18 mm, 24 mm, and 28 mm). The sirolimus-eluting stent was available in fi ve diameters (2·25 mm, 2·50 mm, 2·75 mm, 3·00 mm, and 3·50 mm) and six lengths (8 mm, 13 mm, 18 mm, 23 mm, 28 mm, and 33 mm). We implanted the stents according to standard techniques. We allowed direct stenting without previous balloon dilation. We attempted full lesion coverage by implantation of one or more stents. If several lesions needed to be treated in one patient, the allocated study stent had to be used in all lesions. However, we permitted the use of DES not specifi ed by the random allocation scheme, bare metal stents, and balloon angioplasty if the study stent could not be implanted.
Before implantation, patients received at least 75 mg of aspirin, a 600 mg loading dose of clopidogrel, and an unfractionated heparin dose (5000 IU or 70-100 IU/kg). Glycoprotein IIb/IIIa inhibitors were used at the operator's discretion. Recommended postprocedure dual antiplatelet regi mens were 75 mg aspirin daily lifelong and clopidogrel 75 mg for 1 year. We also used prasugrel treatment as an alternative to clopidogrel, with a loading dose of 60 mg and a daily dose of 10 mg. The primary endpoint was a combination of safety (cardiac death, myocardial infarction, defi nite stent thrombosis) and effi cacy (clinically indicated target vessel revascularisation) within 9 months of stent im plantation. We did intention-to-treat analyses after 9 months and again at 12 months after implantation. Secondary endpoints were: total mortality; cardiac mor tality; myocardial infarction; clinically indicated target lesion or vessel revascularisation; defi nite, probable, or possible stent thrombosis; and device delivery failure.
We defi ned cardiac death as any death due to an evident cardiac cause, any death related to percutaneous coronary intervention, unwitnessed death, or death from unknown causes. Myocardial infarction was de fi ned according to the universal defi nition used by the European Society of Cardiology, the American College of Cardiology, the American Heart Association, and the World Heart Federation. 18 We did not assess biomarkers at the time of the index percutaneous coronary inter vention procedure. We classifi ed stent thrombosis as defi nite, probable, or possible stent thrombosis. 19 We defi ned target vessel revascularisation as any repeat percutaneous coronary intervention or surgical bypass of any segment within the entire major coronary vessel that was proximal or distal to a target lesion, including upstream and downstream branches, and the target lesion itself. We defi ned target lesion revascularisation as repeat revascularisation caused by a more than 50% stenosis within the stent or within a 5 mm border proximal or distal to the stent. Device failure was defi ned as the inability to implant the assigned study stent in a target lesion. To establish comorbidity, we obtained data on hospital diagnoses for all patients from the Danish National Registry of Patients, covering all Danish hospitals from 1977 until the implantation date, 20 and calculated each patient's Charlson comorbidity index score, which covers 19 major disease categories, including diabetes mellitus, heart failure, cerebrovascular diseases, and cancer. 21 We used clinically driven event detection to avoid study-induced re-interventions. We obtained data on mortality, hospital admissions, coronary angiography, repeat percutaneous coronary intervention, and coronary bypass surgery for all randomly allocated patients from the following national Danish administrative and health-care registries: the Civil Registration System; the Western Denmark Heart Registry; 15 the Danish National Registry of Patients 20 (which maintains records for all hospital admissions in Denmark); and the Danish Registry of Causes of Death. 22 An independent event committee, masked to treatment group assignment during the adjudication process, reviewed all endpoints and source documents to adjudicate causes of death, reasons for hospital admission, and diagnosis of myocardial infarction. Two dedicated percutaneous coronary intervention operators at each participating centre reviewed cine fi lms for the event committee to classify stent thrombosis and target vessel revascularisation (either with percutaneous coronary intervention or coronary artery bypass grafting).
The Danish National Health Service provides universal tax-supported health care, guaranteeing residents free access to family doctors and hospitals. The Danish Civil Registration System, which is updated on a daily basis, has kept electronic records on sex, birth date, residence, 
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Statistical analysis
The trial was powered for assessing non-inferiority of the biolimus-eluting stent compared with the sirolimuseluting stent with respect to the primary endpoint at 9 months. On the basis of results from the SORT OUT III trial, 13 we assumed an event rate of 3% in the sirolimuseluting stent group. No valid estimate for event rate in an all-comer population after treatment with the biolimuseluting Nobori stent was available. With a sample size of 1200 patients in each treatment group, a two-group largesample normal approximation test of proportions with a one-sided 0·05 signifi cance level would have 90% power to detect non-inferiority with a predetermined noninferiority margin of 0·02. The sample size of 1200 in each group assumes 0% of patients are lost to follow-up, since we used the Civil Registration System. A Farrington-Manning test was used to test for noninferiority. We compared distri butions of continuous variables between study groups using the two-sample t test (or Cochran test for cases of unequal variance) or the Mann-Whitney U test, depending on whether the data followed a normal distribution. We analysed distributions of categorical variables using the χ² test. In analyses of every endpoint, follow-up continued until the date of an endpoint event, death, emigration, or 12 months after stent implantation, whichever came fi rst. We constructed survival curves based on time to events, accounting for the competing risk of death. 23 Patients who received the sirolimus-eluting stent were used as the reference group for overall and subgroup analyses. We calculated risk diff erences for major adverse cardiac events at 12 month follow-up for prespecifi ed patient subgroups (based on baseline demographic and clinical characteristics). The intention-to-treat principle was used in all analyses. Except for the inferiority testing of the primary endpoint, we regarded a two-sided p value of less than 0·05 to indicate statistical signifi cance. We used Cox proportional hazards regres sion analysis to assess whether diff erence detected at baseline had any eff ect on the result. We did analyses using SAS software (version 9.2). This trial is registered with ClinicalTrials. gov, number NCT01254981.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. They also did not have access to the clinical trial database, nor any opportunity to review the manuscript. The corresponding author had full access to all the data in the study and fi nal responsibility for the decision to submit for publication.
Results
Between July, 2009, to January, 2011, we screened 7570 patients and randomly assigned 2468 patients with 3087 lesions to receive either the biolimus-eluting stent (1229 patients with 1532 lesions) or the sirolimus-eluting stent (1239 patients with 1555 lesions; fi gure 1). 3245 eligible patients were not enrolled, mainly because some operators at the participating centres preferred not to leave stent selection to a randomised process. One patient was lost to follow-up on day 112 because of emigration.
Baseline demographic and clinical characteristics in the two study groups were well balanced except for a slightly higher rate of previous coronary artery bypass grafting in the biolimus-eluting stent group (table 1) . A high proportion of patients in both groups had acute coronary syndromes, multivessel disease, and complex lesions (table 1). Diabetes was equally distributed and reported in 15% of patients. Apart from a higher maximum stent implantation pressure (table 2) and larger reference vessel diam eter in the sirolimus-eluting group, procedure results (such as the rate of device delivery failure and indices of procedure duration, fl uoroscopy time, and use of contrast) and lesion characteristics were similar in the study groups (table 2) .
The 9 month composite primary endpoint occurred in 50 (4·1%) of 1229 patients in the biolimus-eluting stent group and in 39 (3·1%) of 1239 patients in the sirolimuseluting stent group (fi gure 2). With an absolute risk diff erence of 0·9% and the upper limit of the onesided 95% CI at 2·1% (one-sided p non-inferiority =0·06), non-inferiority of the biolimus-eluting stent versus the sirolimus-eluting stent was not shown. Rates of death, cardiac death, myocardial infarction, and clinically driven target vessel revascularisation at 9 months did not diff er signifi cantly between the two stent groups (table 3) . The result was similar for the composite endpoint at 12 months, which occurred in 66 (5·4%) patients in the biolimus-eluting stent group and in 55 (4·4%) patients in the sirolimus-eluting stent group (table 3 and fi gure 2). Defi nite stent thrombosis occurred within 12 months in nine (0·7%) patients in the biolimus-eluting stent group and in two (0·2%) patients in the sirolimus-eluting stent group (p=0·034). We did not detect late defi nite stent thrombosis in any patient. At 12 month follow-up, defi nite or probable stent thrombosis did not diff er between the two groups (table 3) . Clinically driven target lesion revascularisation occurred within 9 months in 30 (2·4%) patients in the Findings for the primary endpoint were consistent across prespecifi ed subgroups (fi gure 3). Specifi cally, the primary endpoint did not diff er signifi cantly between the two stent groups in patients with and without diabetes mellitus. Due to the small imbalance in proportion of patients with previous coronary artery bypass graft and diff erence in reference vessel diameter between groups, we adjusted for these variables with Cox proportional hazards regression analysis. This did not change the results (data not shown).
Results of per-protocol analysis showed that 45 (3·8%) of 1193 patients who received a biolimus-eluting stent and 39 (3·2%) of 1208 patients who received the sirolimus-eluting stent met the primary endpoint (risk diff erence 0·5% [upper limit of one-sided 95% CI 1·8%]; p non-inferiority =0·03).
Discussion
Our SORT OUT V trial is the largest head-tohead comparison of the biodegradable polymer-coated biolimus-eluting Nobori stent and the permanent polymer-coated sirolimus-eluting Cypher stent. 9 At 9 and 12 month assessment of clinical safety and effi cacy, the results of the study did not show non-inferiority of the biolimus-eluting stent compared with the sirolimuseluting stent.
This result contrasts with that of the LEADERS trial, which also compared a biolimus-eluting biodegradable polymer-coated stent with the sirolimus-eluting Cypher stent. 10 The biodegradable stent of the LEADERS trial (BioMatrix Flex, Biosensors, Newport Beach, CA, USA) is almost identical to the Nobori stent used in our study. The stent platforms are made of the same stainless steel alloy and the biodegradable polymer is the same. However, the Nobori stent has an ultra-thin non-degradable parylene coating between the stent and the biodegradable polymer to assure polymer attachment to the stent struts.
In the LEADERS trial, the event rate for the primary endpoint for both stents was almost twice as high as in SORT OUT V, and the investigators concluded that the biodegradable polymer study stent was non-inferior to the sirolimus-eluting stent. 10 By contrast with the LEADERS trial, we did not routinely assess pro cedural biomarkers, and did not record asymptomatic and electrocardiograph silent procedure-related myo cardial damage. The higher rate of new revascularisations in the LEADERS trial (4·4% with the biolimus-eluting stent vs 5·5% with the sirolimuseluting stent) compared with our trial (3·3% vs 2·1%) might be explained by the fact that 25% of patients in the LEADERS trial had a prescheduled angiography followup. 24 Further more, the rate of diabetes was twice as high in the LEADERS trial as in our trial in which 15% of patients had diabetes, a rate that is characteristic for interventional studies in Nordic countries.
We cannot explain why, in our trial, the 12 month event rates in the biolimus-eluting stent group were higher than those in the sirolimus-eluting stent group. Although non-signifi cant, the diff erence was noted in all elements of the combined endpoint and across patient subgroups. The diff erences seemed to occur mainly during the fi rst month and were most pronounced in the endpoints of stent thrombosis, myocardial infarction, and new revascularisations (fi gure 2). We cannot exclude that the non-degradable parylene coating between the stent and the biodegradable polymer, covering the entire stent, might be a causal factor. Other explanations might be the signifi cant, but small, diff erence in implantation pressures between the two groups, with a possibly improved apposition 
Events at 30 days
All-cause mortality 8 (0·7%) 7 (0·6%) 0·1% (−0·5 to 0·7) 0·78
Cardiac death 6 (0·5%) 6 (0·5%) 0·0% (−0·5 to 0·6) 0·99
Myocardial infarction 10 (0·8%) 3 (0·2%) 0·6% (0·0 to 1·1) 0·050
Target vessel revascularisation 14 (1·1%) 8 (0·6%) 0·5% (−0·2 to 1·2) 0·19
Target lesion revascularisation 11 (0·9%) 7 (0·6%) 0·3% (−0·3 to 1·0) 0·34
Defi nite stent thrombosis 9 (0·7%) 2 (0·2%) 0·6% (0·0 to 1·1) 0·034
Events at 9 months
Composite primary endpoint* 50 (4·1%) 39 (3·1%) 0·9% (−0·6 to 2·4) 0·22 between stent struts and vessel wall in the patients who received the sirolimus-eluting stent. The SORT OUT IV study documented similar safety and effi cacy between the sirolimus-eluting Cypher stent and the second-generation everolimus-eluting Xience V stent. 14 The COMPARE II trial randomly assigned 2707 patients (2:1) to the biolimus-eluting Nobori stent or an everolimus-eluting stent (Xience V or Prime, Abbott Vascular, Santa Clara, CA, USA, or Promus, Boston Scientifi c, Natick, MA, USA; panel). 25 Although the event rates in the biolimus-eluting stent group were numerically higher than in the everolimus-eluting stent group, the study showed non-inferiority of the biolimuseluting stent. At 12 months, rates of major cardiac events at 12 months were 5·2% with the biolimus-eluting stent versus 4·8% with the everolimus-eluting stent and the rates of defi nite stent thrombosis were 0·7% versus 0·4%. These results are similar to those reported in our study (5·4% with the biolimus-eluting stent vs 4·4% with the sirolimus-eluting stent for major cardiac events and 0·7% vs 0·2% for defi nite stent thrombosis), so despite our study not showing non-inferiority, our results are backed up by 12 month safety and effi cacy data from COMPARE II, which also compared an older-generation DES with the biolimus-eluting Nobori stent.
Very late stent thrombosis (generally defi ned as occur ring >1 year after implantation) has been a weakness of fi rst-generation DES. Therefore, our follow-up 
Panel: Research in context
Systematic review
We searched PubMed, EuroPCR, and Transcatheter Cardiovascular Therapeutics (TCT) conferences for reports on randomised trials comparing the biolimus-eluting biodegradable polymer-coated Nobori stent with durable polymer stents powered for clinical endpoints with the search terms "Nobori", "stent", "randomised", or "randomized", published between Jan 1, 2003, and June 1, 2012. We identifi ed the COMPARE II trial, 25 which randomly assigned (2:1) 2707 patients to the biolimus-eluting Nobori stent or an everolimus-eluting stent. At 12 months, the rates of major adverse cardiac events and defi nite stent thrombosis were higher in the biolimus-eluting stent group than in the everolimus-eluting stent group, but using a non-inferiority margin of 4%, the investigators concluded non-inferiority of the biolimus-eluting stent. We identifi ed additional reports cited in this Article by searching PubMed with the term "biolimus-eluting stent".
Interpretation
Our study and the COMPARE II trial show that at 1 year, the biodegradable polymer biolimus-eluting Nobori stent does not improve clinical results compared with the fi rst-generation sirolimus-eluting or everolimus-eluting durable polymer stents. However, long-term data will be needed before we can make recommendations for the role of the Nobori stent in routine clinical practice.
of 12 months is too short to off er a complete description of the safety profi le of the biolimus-eluting stent. In the NOBORI 2 study, 26 which assessed the biolimus-eluting Nobori stent, very low stent thrombosis rates were seen 12-24 months (0·10%) 26 and 24-36 months (0·10%) after implantation. 27 By contrast, results of the LEADERS trial showed that the sirolimus-eluting Cypher stent has a yearly incidence of very late stent thrombosis of about 0·6%. 10 Therefore, we postulate that our results might show non-inferiority of the biolimus-eluting stent versus the sirolimus-eluting stent in the longer term. Accordingly, a meta-analysis of three ran domised clinical trials with 2 or more years' follow-up reported that biodegradable, as compared with durable, polymer DES were associated with a reduced risk of defi nite stent thrombosis and target lesion revascularisation. 28 The second-generation everolimus-eluting stent with a permanent fl uoropolymeric polymer seems to be an exception to this fi nding, and so far it has not been associated with longterm safety problems. 29 In conclusion, the SORT OUT V study did not show non-inferiority of the biolimus-eluting Nobori stent compared with the sirolimus-eluting Cypher stent at 12 months.
